Sandbox Reserved 1177

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 28: Line 28:
===Active State===
===Active State===
-
After determining <scene name='72/721547/Ntsr1-gw5/8'>NTSR1-GW5</scene> as only active-like, research was conducted to determine the structure of NTSR1 with catalytic nucleotide exchange. In order to do so, three of the six mutations were reverted back <ref name="SPGP"/>, and these three residues were selected on the basis of their location. The reversion of E166A, L310A, and F358A led to NTSR1 with G-protein activity at almost wild-type level. This protein was named, <scene name='72/721548/Ntsr1-elf/3'>NTSR1-ELF</scene>, and indicated that the amino acid residues E166, L310, and F358 play significant roles in the activity of NTSR1 <ref name="SPGP"/>.
+
After determining <scene name='72/721547/Ntsr1-gw5/8'>NTSR1-GW5</scene> as only active-like, research was conducted to determine the structure of NTSR1 with catalytic nucleotide exchange. In order to do so, three of the six mutations were reverted back <ref name="SPGP"/>, and these three residues were selected on the basis of their location. The reversion of E166A, L310A, and F358A led to NTSR1 with G-protein activity at almost wild-type level. This protein was named, <scene name='72/721548/Ntsr1-elf/6'>NTSR1-ELF</scene>, and indicated that the amino acid residues E166, L310, and F358 play significant roles in the activity of NTSR1 <ref name="SPGP"/>.
====Leu310====
====Leu310====

Revision as of 03:52, 21 April 2016

An interactive view of the class A GPCR, NTSR1 (blue). This protein gets its activity from binding to the 13 amino acid ligand, NTS (red).

Drag the structure with the mouse to rotate

References

  1. 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 1.15 1.16 Krumm BE, White JF, Shah P, Grisshammer R. Structural prerequisites for G-protein activation by the neurotensin receptor. Nat Commun. 2015 Jul 24;6:7895. doi: 10.1038/ncomms8895. PMID:26205105 doi:http://dx.doi.org/10.1038/ncomms8895
  2. 2.0 2.1 2.2 2.3 2.4 2.5 White JF, Noinaj N, Shibata Y, Love J, Kloss B, Xu F, Gvozdenovic-Jeremic J, Shah P, Shiloach J, Tate CG, Grisshammer R. Structure of the agonist-bound neurotensin receptor. Nature. 2012 Oct 25;490(7421):508-13. doi: 10.1038/nature11558. Epub 2012 Oct 10. PMID:23051748 doi:http://dx.doi.org/10.1038/nature11558
  3. 3.0 3.1 3.2 3.3 Liang Y, Boules M, Li Z, Williams K, Miura T, Oliveros A, Richelson E. Hyperactivity of the dopaminergic system in NTS1 and NTS2 null mice. Neuropharmacology. 2010 Jun;58(8):1199-205. doi:, 10.1016/j.neuropharm.2010.02.015. Epub 2010 Mar 6. PMID:20211191 doi:http://dx.doi.org/10.1016/j.neuropharm.2010.02.015
  4. 4.0 4.1 4.2 Carraway RE, Plona AM. Involvement of neurotensin in cancer growth: evidence, mechanisms and development of diagnostic tools. Peptides. 2006 Oct;27(10):2445-60. Epub 2006 Aug 2. PMID:16887236 doi:http://dx.doi.org/10.1016/j.peptides.2006.04.030
  5. 5.0 5.1 5.2 Griebel G, Holsboer F. Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning? Nat Rev Drug Discov. 2012 May 18;11(6):462-78. doi: 10.1038/nrd3702. PMID:22596253 doi:http://dx.doi.org/10.1038/nrd3702
Personal tools